Key terms
About RNLX
Renalytix Plc engages in the manufacturing of medical devices and equipment. It includes the development of artificial intelligence-enabled clinical diagnostic solutions for kidney disease. The company was founded by James McCullough on March 15, 2018 and is headquartered in New York, NY.
Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
52-week range
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date
Key terms
Ad Feedback
Smart score
Latest RNLX news
Apr 23
5:13pm ET
Renalytix AI Announces Fundraising, Executive Changes, and Shareholder Approval
Apr 17
4:50pm ET
Renalytix files to sell 19.99M ordinary shares for holders
Apr 08
7:52am ET
Renalytix AI Announces Non-Filed $4 Million Financing Plan
Apr 08
7:20am ET
Renalytix announces financing with expected size up to $4M
Mar 14
7:32am ET
Renalytix AI’s KidneyIntelX™ Endorsed in KDIGO Guidelines
Mar 04
6:55pm ET
Buy Rating Affirmed for Renalytix AI Amidst Potential Acquisition and Strong Market Prospects
Mar 01
7:50am ET
Renalytix AI (RNLX) Receives a Buy from Stifel Nicolaus
Feb 29
6:22am ET
Renalytix AI Secures Government Contract and Awaits Medicare Decision
Feb 15
7:13am ET
Renalytix reports Q2 EPS (9c) vs. (14c) last year
Feb 10
4:03am ET
Renalytix AI Anticipates Medicare Coverage Milestone
Feb 09
8:31am ET
Analysts Offer Insights on Healthcare Companies: Xenon (XENE), Disc Medicine (IRON) and Renalytix AI (RNLX)
Feb 08
3:45pm ET
Strong Buy for Renalytix AI: Undervalued Stock with Promising Market Prospects and Strategic Growth Catalysts
Feb 08
3:34pm ET
Renalytix draft LCD a ‘major catalyst,’ says BTIG
No recent press releases are available for RNLX
RNLX Financials
Key terms
Ad Feedback
RNLX Forecasts
analyst rating
- buy
- hold
- sell
1-year stock price forecast
RNLX Competitors
$ Market cap
P/E ratio
$ Price
1d change
52-week range
